Abstract
Patients after surgical repair of tetralogy of Fallot (TOF) may experience various complications that result in neurohormonal activation, including plasma B-type natriuretic peptide (BNP) elevation. Right ventricular (RV) dilation is a frequent complication, and few treatments are available. This study aimed to identify the factor or factors leading to BNP elevation and to clarify the effects of angiotensin-converting enzyme inhibitor (ACE-I) on changes in BNP levels in patients with repaired TOF. Plasma BNP levels and hemodynamic data derived from cardiac catheterization were analyzed. In addition, longitudinal BNP levels and ACE-I dosages were analyzed for patients administered ACE-I. For 31 patients with repaired TOF, who mainly had RV dilation, log BNP levels were significantly correlated with the RV end-diastolic volume index (P = 0.02) as well as ventricular volume and pressure (P < 0.01). For 11 patients medicated with ACE-I, BNP levels were significantly lower at the time of maximal ACE-I dosage than at the time of minimal dosage (P < 0.01). Furthermore, BNP levels decreased as the ACE-I dosage per body weight increased (P < 0.01). In conclusion, elevation of BNP in patients after TOF repair could reflect volume and pressure load in the RV end-diastolic phase, and ACE-I may reduce BNP levels in a dose-dependent manner.
Similar content being viewed by others
References
Adamson L, Vohra HA, Haw MP (2009) Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interactive Cardiovasc Thorac Surg 9:520–527
Alter P, Rupp H, Rominger MB, Vollrath A, Czerny F, Klose KJ, Maisch B (2007) Relation of B-type natriuretic peptide to left ventricular wall stress as assessed by cardiac magnetic resonance imaging in patients with dilated cardiomyopathy. Can J Physiol Pharmacol 85:790–799
Apitz C, Sieverding L, Latus H, Uebing A, Schoof S, Hofbeck M (2009) Right ventricular dysfunction and B-type natriuretic peptide in asymptomatic patients after repair for tetralogy of Fallot. Pediatr Cardiol 30:898–904
Çetin Í, Tokel K, Varan B, Örün UA, Gökdemir M, Cındık N, Eyüboğlu F, Ulubay G, Aşlamacı S (2008) Evaluation of right ventricular functions and B-type natriuretic peptide levels by cardiopulmonary exercise test in patients with pulmonary regurgitation after repair of tetralogy of Fallot. J Card Surg 23:493–498
Cheung EW, Wong WH, Cheung Y (2010) Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of Fallot. Am J Cardiol 106:552–557
Dodge-Khatami A, Büchel EV, Knirsch W, Kadner A, Rousson V, Dave HH, Bauersfeld U, Prêtre R (2006) Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular dilatation. Ann Thorac Surg 82:983–988
Gatzoulis MA, Till JA, Somerville J, Redington AN (1995) Mechanoelectrical interaction in tetralogy of Fallot: QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 92:231–237
Gatzoulis MA, Balaji S, Webber SA (2000) Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 356:975–981
Geva T (2006) Indications and timing of pulmonary valve replacement after tetralogy of Fallot repair. Semin Thorac Cardiovasc Surg Pediatr Card Surg Ann 9:11–22
Graham TP, Jarmakani JM, Canent RV, Morrow M (1971) Left heart volume estimation in infancy and childhood: reevaluation of methodology and normal values. Circulation 43:895–904
Graham TP, Jarmakani JM, Atwwod GF, Canent RV (1973) Right ventricular volume determinations in children: normal values and observations with volume or pressure overload. Circulation 47:144–153
Harrild DM, Berul CI, Cecchin F, Geva T, Gauvreau K, Pigula F, Walsh EP (2009) Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation 119:445–451
Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, Downar E, McLaughlin PR, Williams WG (1997) Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. JACC 30:1368–1373
Hazama K, Nakazawa M, Momma K (2001) Effective dose and cardiovascular effects of cilazapril in children with heart failure. Am J Cardiol 88:801–805
Hickey EJ, Veldtman G, Bradley TJ, Gengsakul A, Manlhiot C, Williams WG, Webb GD, McCrindle BW (2009) Late risk of outcomes for adults with repaired tetralogy of Fallot from an inception cohort spanning four decades. Eur J Cardiothorac Surg 35:156–166
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation 112:e154–e235
Khositseth A, Manop J, Khowsathit P, Siripornpitak S, Pornkul R, Lolekha P, Attanawanich S (2007) N-terminal pro-brain natriuretic peptide as a marker in follow-up patients with tetralogy of Fallot after total correction. Pediatr Cardiol 28:333–338
Knauth AL, Gauvreau K, Powell AJ, Landzberg MJ, Walsh EP, Lock JE, del Nido PJ, Geva T (2008) Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart 94:211–216
Koch A, Zink S, Singer H (2006) B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 27:861–866
Koch AM, Zink S, Glöckler M, Seeliger T, Dittrich S (2009) Plasma levels of B-type natriuretic peptide in patients with tetralogy of Fallot after surgical repair. Int J Cardiol 143:130–134
Lindsey CW, Parks WJ, Kogon BE, Sallee D III, Mahle WT (2010) Pulmonary valve replacement after tetralogy of Fallot repair in preadolescent patients. Ann Thorac Surg 89:147–151
Ma ZS, Ma SJ, Dong MF, Wang JT, Wang LX (2009) Effect of captopril on pulmonary artery pressure following corrective surgery for tetralogy of Fallot. J Card Surg 24:553–557
Maeder MT, Mariani JA, Kaye DM (2010) Hemodynamic determinants of myocardial B-type natriuretic peptide release relative contributions of systolic and diastolic wall stress. Hypertension 56:682–689
Miyazaki A, Yamamoto M, Sakaguchi H, Tsukano S, Kagisaki K, Suyama K, Ohuchi H, Kurosaki K, Yagihara T, Yamada O (2009) Pulmonary valve replacement in adult patients with a severely dilated right ventricle and refractory arrhythmias after repair of tetralogy of Fallot. Circ J 73:2135–2142
Momma K (2006) ACE inhibitors in pediatric patients with heart failure. Paediatr Drugs 8:55–69
Mori Y, Nakazawa M, Tomimatsu H, Momma K (2000) Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study. J Am Coll Cardiol 36:270–275
Muhlla IV, Liub P, Webb G (2004) Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. Int J Cardiol 97:25–33
Niwa K, Hamada H, Nakazawa M, Terai M, Tateno S, Sugimoto S, Watanabe H, Murakami A, Ohta M, Ishizawa A, Katoki T, Mori K, Yasui S, Kawahira Y, Akagi T, Haraguchi N, Gatzoulis MA (2002) Mortality and risk factors for late deaths in tetralogy of Fallot: the Japanese nationwide multicentric survey. Cardiol Young 12:453–460
Norozi K, Buchhorn R, Kaiser C, Hess G, Grunewald RW, Binder L, Wessel A (2005) Plasma N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest 128:2563–2570
Norozi K, Buchhorn R, Bartmus D, Alpers V, Arnhold JO, Schoof S, Zoege M, Binder L, Geyer S, Wessel A (2006) Elevated brain natriuretic peptide and reduced exercise capacity in adult patients operated on for tetralogy of Fallot is due to biventricular dysfunction as determined by the myocardial performance index. Am J Cardiol 97:1377–1382
Oosterhof T, Tulevski II, Vliegen HW, Spijkerboer AM, Mulder BJ (2006) Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am J Cardiol 97:1051–1055
Parekh N, Maisel AS (2009) Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function and diastolic heart failure. Curr Opin Cardiol 24:155–160
Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 170:507–514
Tirilomis T, Friedrich M, Zenker D, Seipelt RG, Schoendube FA, Ruschewski W (2010) Indications for reoperation late after correction of tetralogy of Fallot. Cardiol Young 20:396–401
Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, Starling RC, Young JB, Thomas JD, Klein AL (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43:416–422
Frigiola A, Tsang V, MD, Bull C, Coats L, Khambadkone S, Derrick G, Mist B, Walker F, Doorn CV, Bonhoeffer P, Taylor AM (2008) Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: is age a predictor of outcome? Circulation 118:S182–S190
Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD (2008) ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 118:2395–2451
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Furukawa, T., Murakami, T., Ueno, M. et al. The Cause of B-Type Natriuretic Peptide Elevation and the Dose-Dependent Effect of Angiotensin-Converting Enzyme Inhibitor on Patients Late After Tetralogy of Fallot Repair. Pediatr Cardiol 33, 264–271 (2012). https://doi.org/10.1007/s00246-011-0135-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-011-0135-1